Abbott Secures Sweeping Injunction Against SiBio’s GS3-R CGM System at Unified Patent Court, Intensifying IP Disputes in Medtech

September 13, 2026

Facebook USA

Overview

Abbott Diabetes Care has secured a broad preliminary injunction from the Unified Patent Court (UPC) against SiBio’s GS3-R continuous glucose monitoring (CGM) system, effective September 10, 2026. This significant ruling halts the manufacture, import, and marketing of SiBio’s device across 18 UPC member states, underscoring the escalating intellectual property disputes within the competitive and fast-expanding CGM market. The decision highlights the crucial role of robust patent portfolios and strategic IP defense for major players in the medical device sector.

In Depth

Background & Context

The continuous glucose monitoring (CGM) market has witnessed remarkable growth in recent years, with its technology profoundly enhancing diabetes patient self-management and overall quality of life. Abbott’s FreeStyle Libre series and Dexcom’s G-series stand as key innovators in this sector, having invested substantially in technological advancement and strategic patent acquisition. As the market expands and competition intensifies, intellectual property (IP) disputes are becoming increasingly common, representing a strategic effort by companies to secure market share and maintain technological superiority. Notably, the Unified Patent Court (UPC) represents a novel European framework capable of adjudicating patent disputes across multiple countries within a single jurisdiction, and this latest ruling powerfully underscores its growing influence.

Key Findings

On September 10, 2026, Abbott Diabetes Care announced it had successfully obtained a broad preliminary injunction from the Unified Patent Court (UPC) against SiBio’s GS3-R continuous glucose monitoring (CGM) system. This decisive ruling effectively bans the manufacturing, importing, and marketing of SiBio’s GS3-R system across 18 UPC member states, encompassing a significant portion of the European Union. This substantial legal victory starkly highlights the paramount importance of robust intellectual property rights protection and the fierce competition among leading players in the rapidly expanding CGM market.

Technical & Clinical Details

The preliminary injunction was granted following Abbott’s allegations of patent infringement. It is understood that Abbott possesses patents covering innovative sensor technologies, signal processing algorithms, or specific device structures originally developed for its highly successful FreeStyle Libre system. SiBio’s GS3-R system was accused of incorporating elements of Abbott’s patented glucose monitoring technology. The UPC found that Abbott had presented credible evidence of patent infringement and that the company would likely incur irreparable harm if the injunction were not imposed. This ruling powerfully illustrates how actively companies within the rapidly innovating medical device sector, particularly in high-growth areas like CGM, utilize intellectual property rights to safeguard their substantial research and development investments. Consequently, the affected SiBio GS3-R system will either need to be temporarily removed from the market or undergo a significant redesign to circumvent the patent infringement claims.

Strategic Significance & Outlook

Abbott’s successful procurement of this preliminary injunction signals that intellectual property rights protection within the CGM market will become even more paramount in the foreseeable future. For SiBio, this necessitates a fundamental reassessment of its long-term business strategy, while for other market competitors, it serves as a critical reminder to re-evaluate their respective technology portfolios and patent strategies. While such vigorous legal actions can undoubtedly foster innovation by rewarding R&D, they can also inadvertently create formidable barriers to market entry for nascent and smaller companies. Looking ahead, CGM technology is anticipated to evolve further, offering enhanced functionalities (e.g., simultaneous monitoring of biomarkers beyond glucose), greater miniaturization, and extended wear durations. Nevertheless, robust patent portfolios and the astute ability to navigate intricate IP landscapes will remain indispensable for both the development and widespread market deployment of these advanced systems. This ruling truly symbolizes a new and intense phase of competition within this highly innovative healthcare technology sector.

Source: https://www.facebook.com/LifeSciencesIPReview/posts/abbott-diabetes-care-has-won-a-broad-preliminary-injunction-at-the-unified-paten/1408538641286995/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.